Understanding how HIF2 affects pancreatic cancer growth
The Role of HIF2 in Pancreatic Ductal Adenocarcinoma
This study is looking at how a protein called HIF2 in certain cells around pancreatic cancer tumors might help the cancer survive treatment by making the area low in oxygen, and researchers want to see if getting rid of HIF2 can slow down the tumor's growth and improve outcomes for patients with this tough cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11210731 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called HIF2 in pancreatic ductal adenocarcinoma (PDAC), a type of aggressive cancer. The study focuses on how HIF2 in cancer-associated fibroblasts (CAFs) contributes to the tumor's ability to resist treatment by creating a low-oxygen environment. Using a specially designed mouse model, researchers will explore the effects of removing HIF2 from CAFs on tumor growth and survival rates. The findings aim to uncover new therapeutic targets that could improve treatment outcomes for patients with this challenging cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who may benefit from novel therapeutic strategies.
Not a fit: Patients with other types of cancer or those not diagnosed with pancreatic ductal adenocarcinoma may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the effectiveness of therapies for pancreatic cancer patients.
How similar studies have performed: Previous research has shown promising results in targeting hypoxia-related pathways in cancer, suggesting that this approach may yield significant insights.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Koong, Albert — University of Tx Md Anderson Can Ctr
- Study coordinator: Koong, Albert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.